
    
      Phase 3, multi-center, randomized withdrawal study to evaluate the sustained benefit in
      efficacy and safety of ampreloxetine in subjects with primary autonomic failures (MSA, PD, or
      PAF) and symptomatic nOH. The study consists of 3 periods: (i) 16-week open-label (OL)
      treatment with ampreloxetine, (ii) 6-week randomized placebo-controlled treatment, and (iii)
      2-week follow-up (only for patients who do not enroll in Study 0171 (long-term extension
      safety study)).
    
  